Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will address the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and will highlight Annovis’ approach of simultaneously targeting multiple neurotoxic proteins through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company’s unique multi-protein approach sets it apart from traditional treatments that target single proteins.
The presentation at Fierce Biotech Week 2026 is significant because it underscores the growing recognition that Alzheimer’s disease involves multiple pathological proteins, and that effective therapies may need to address this complexity. Annovis’ strategy of targeting several neurotoxic proteins simultaneously could potentially offer more comprehensive disease modification. The company is headquartered in Malvern, Pennsylvania, and focuses on both Alzheimer’s disease and Parkinson’s disease.
For more information about Annovis Bio and its pipeline, visit the company’s website at www.annovisbio.com. The full press release is available at https://ibn.fm/kZ2Z4. Investors can find the latest news and updates relating to ANVS in the company’s newsroom at https://ibn.fm/ANVS.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s lead drug candidate, buntanetap, is designed to inhibit the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The upcoming presentation at Fierce Biotech Week 2026 provides a platform to discuss the scientific rationale behind this multi-protein approach and its potential implications for Alzheimer’s treatment.
